Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.

Carine BeysenPatricia SchroederEric WuJulie BrevardMaria RibadeneiraWei LuKiran DoleTerry O'ReillyLinda MorrowMarcus HompeschMarc K HellersteinKelvin LiLars JohanssonPatrick F Kelly

Published in: Diabetes, obesity & metabolism (2020)

Inhibition of FASN with 3 mg FT-4101 safely reduces hepatic DNL and steatosis in NAFLD patients.

Keyphrases

fatty acid
insulin resistance
end stage renal disease
high fat diet induced
high fat diet
newly diagnosed
ejection fraction
chronic kidney disease
adipose tissue
metabolic syndrome
type diabetes
prognostic factors
weight loss
skeletal muscle